ARCT compared with NTLA: revenue, margins and what each company keeps, and the suppliers and customers both name

ARCTArcturus Therapeutics Holdings Inc.

Mkt capRevenueRevenue

NTLAIntellia Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

ARCTArcturus Therapeutics Holdings Inc.

NTLAIntellia Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ARCT

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±16.3%▲+10.58%×0.65

Q2 FY26±21.8%▲+21.88%×1.00

May 8 '26±15.5%▲+3.60%×0.23

Q1 FY26±18.3%▼−4.17%×0.23

NTLA

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±14.2%▼−9.83%×0.69

Q2 FY26±12.8%▲+2.46%×0.20

= impliedARCT realized, solidNTLA realized, hatchedOne scale, both sides: full bar = 22%× = |realized| ÷ impliedSource: market data

May 11 '26

±7.2%

▲+2.34%

×0.32

Q1 FY26±18.7%▲+6.41%×0.34

ARCTArcturus Therapeutics Holdings Inc.

10.36▲+10.67%· post 10.36

Mkt cap$298.3MRevenue$18MQ3 FY26Revenue$82MFY25

NTLAIntellia Therapeutics, Inc.

11.35▲+2.23%· post 11.31

ClosedNov 6 '26

Mkt cap$1.6BRevenue$7MQ3 FY26Revenue$68MFY25

Compare

ClosedNov 6 '26

ARCTArcturus Therapeutics Holdings Inc.

NTLAIntellia Therapeutics, Inc.

10.36▲+10.67%post 10.36

Price

11.35▲+2.23%post 11.31

$298.3M

Mkt cap

$1.6B

Q3 FY26$18M

Revenue

$7MQ3 FY26

FY25$82M

Revenue

$68MFY25

ARCT10.36▲+10.67%vsNTLA11.35▲+2.23%ClosedNov 6 '26